RCKT vs. XBI
Compare and contrast key facts about Rocket Pharmaceuticals, Inc. (RCKT) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Performance
RCKT vs. XBI - Performance Comparison
Loading graphics...
RCKT vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RCKT Rocket Pharmaceuticals, Inc. | 1.99% | -72.08% | -58.06% | 53.14% | -10.35% | -60.19% | 140.95% | 53.58% | 41.95% | -57.21% |
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
Returns By Period
In the year-to-date period, RCKT achieves a 1.99% return, which is significantly lower than XBI's 4.76% return. Over the past 10 years, RCKT has underperformed XBI with an annualized return of -19.29%, while XBI has yielded a comparatively higher 9.32% annualized return.
RCKT
- 1D
- 3.92%
- 1M
- -28.54%
- YTD
- 1.99%
- 6M
- 9.82%
- 1Y
- -46.33%
- 3Y*
- -40.66%
- 5Y*
- -39.78%
- 10Y*
- -19.29%
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RCKT vs. XBI — Risk / Return Rank
RCKT
XBI
RCKT vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rocket Pharmaceuticals, Inc. (RCKT) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RCKT | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.42 | 2.02 | -2.44 |
Sortino ratioReturn per unit of downside risk | 0.16 | 2.70 | -2.54 |
Omega ratioGain probability vs. loss probability | 1.03 | 1.34 | -0.31 |
Calmar ratioReturn relative to maximum drawdown | -0.75 | 3.72 | -4.47 |
Martin ratioReturn relative to average drawdown | -0.99 | 13.98 | -14.97 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| RCKT | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.42 | 2.02 | -2.44 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.51 | -0.04 | -0.47 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.23 | 0.29 | -0.52 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.16 | 0.36 | -0.51 |
Correlation
The correlation between RCKT and XBI is 0.61, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
RCKT vs. XBI - Dividend Comparison
RCKT has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.34%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RCKT Rocket Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
RCKT vs. XBI - Drawdown Comparison
The maximum RCKT drawdown since its inception was -96.70%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for RCKT and XBI.
Loading graphics...
Drawdown Indicators
| RCKT | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.70% | -63.89% | -32.81% |
Max Drawdown (1Y)Largest decline over 1 year | -70.91% | -13.39% | -57.52% |
Max Drawdown (5Y)Largest decline over 5 years | -95.24% | -55.04% | -40.20% |
Max Drawdown (10Y)Largest decline over 10 years | -96.46% | -63.89% | -32.57% |
Current DrawdownCurrent decline from peak | -94.93% | -26.17% | -68.76% |
Average DrawdownAverage peak-to-trough decline | -68.09% | -20.91% | -47.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 53.33% | 3.71% | +49.62% |
Volatility
RCKT vs. XBI - Volatility Comparison
Rocket Pharmaceuticals, Inc. (RCKT) has a higher volatility of 33.33% compared to SPDR S&P Biotech ETF (XBI) at 11.60%. This indicates that RCKT's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| RCKT | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.33% | 11.60% | +21.73% |
Volatility (6M)Calculated over the trailing 6-month period | 57.42% | 19.25% | +38.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 110.77% | 29.24% | +81.53% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.25% | 32.23% | +46.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.16% | 32.15% | +52.01% |